Summary: In a multicentre trial in Chinese adults with poorly controlled type 2 diabetes, a 12-month text-message programme produced a modest net improvement in HbA1c (-0.3%) and systolic pressure (-2.4 mmHg) and got more patients to glycaemic goal, but did not change LDL cholesterol.
PICO Summary
| Element | Detail |
|---|---|
| Population | 819 adults with uncontrolled type 2 diabetes (mean HbA1c 10.2%) and cardiovascular risk factors; 5 centres, China. |
| Intervention | Six motivational and reminder text messages per week for 12 months (n=410). |
| Comparison | Usual care (n=409); intention-to-treat analysis. |
| Outcome | Net differences: HbA1c -0.3% (95% CI -0.5 to 0.0), systolic pressure -2.4 mmHg (-4.3 to -0.4), LDL not significantly different (combined effect p=0.001). More patients reached HbA1c goal at 12 months (54.0% vs 46.1%; p=0.04). |
Text-Message Programme in Uncontrolled T2DM
RCT · type 2 diabetes · 12 months
A 12-month text-message programme modestly lowered HbA1c and systolic pressure and got more patients to glycaemic goal, but did not change LDL. A low-cost adjunct, not a substitute for medication intensification.
Expert Commentary
This is a well-conducted, appropriately titled trial whose honesty about effect size is its strength. Text messaging is the minimum viable digital intervention, no app, no smartphone required, and at population scale even small average gains can matter, so a net HbA1c reduction of 0.3% and a modest blood-pressure fall, with more patients crossing into the controlled range, is a genuine if undramatic result. The most important clinical lesson sits in the baseline: these patients started at an HbA1c of 10.2%, severely uncontrolled, and the modest response underlines that messaging supports behaviour but cannot substitute for the medication intensification such patients clearly need. The neutral LDL result reinforces that limit. The caveats are appropriate: the effect sits right at the margin of significance, the setting is specific to China, and durability after messaging stops is untested. Can I use this with my patients? Yes, as an adjunct with realistic expectations. It supports adding structured, culturally tailored reminders to clinical care for patients who struggle between visits, while being explicit that for anyone with markedly elevated HbA1c the priority is escalating pharmacotherapy, with messaging as a low-cost complement rather than the treatment.
References
Zhang PZ, Guo D, Liu CQ, et al. Mobile app-based intervention and cardiovascular risk factors in patients with uncontrolled type 2 diabetes: a randomized clinical trial. JAMA Netw Open. 2025;8(9):e2529762. doi:10.1001/jamanetworkopen.2025.29762